| PACKAGING TYPE: | 10x10 Alu-alu (10 Strips In 1 Box) |
| COMPOSITION: | Repaglinide (1mg) + Voglibose (0.2mg) |
| FORMULATION: | Tablet |
| Description: | REPAMADE V1/0.2 Tablet is a combination of Repaglinide 1 mg and Voglibose 0.2 mg. It is used for the management of type 2 diabetes mellitus, particularly in patients who require better control of postprandial (after-meal) blood glucose levels. Repaglinide stimulates insulin release from the pancreas, while Voglibose delays carbohydrate absorption in the intestine, providing dual-action glycemic control. |
| Side Effects: | Common: Hypoglycemia (low blood sugar) Flatulence Abdominal discomfort Diarrhea Serious (Rare): Severe hypoglycemia Liver function abnormalities Allergic reactions (rash, swelling, difficulty breathing) |
| How to Use: | Take as prescribed by a healthcare professional Usually taken before meals Swallow the tablet with water Follow dietary recommendations for best results Regular blood glucose monitoring is advised |
| Precaution: | Monitor blood sugar levels regularly Use with caution in patients with liver or kidney disorders Avoid alcohol as it may increase risk of hypoglycemia Inform your doctor about all medications being taken Not recommended during pregnancy or breastfeeding unless prescribed |
| Product Benefits: | Provides effective control of post-meal blood sugar spikes Dual mechanism enhances glycemic management Improves overall blood glucose control Reduces risk of diabetes-related complications Suitable for combination therapy in type 2 diabetes |
Frequently Asked Questions
It is used for type 2 diabetes mellitus to control post-meal blood sugar levels.
Repaglinide increases insulin secretion, while Voglibose delays carbohydrate absorption, providing dual glycemic control.
Yes, under medical supervision with regular monitoring of blood glucose levels.




















